Moderna Inc. plans to double enrollment in a trial of its Covid vaccine in children under age 12, following a request from U.S. regulators to collect additional safety data. Dangerous Covid infections in children have raised increasing concerns as the delta variant spreads across the U.S., and the fall resumption of classes looms. Moderna said last month that it would expand the trial at the request of U.S. regulators, who were seeking additional data amid worries that messenger RNA shots may trigger rare heart side effects. Pfizer Inc. and its partner BioNTech SE have also said they intend to expand the size of their under-12 study. Pfizer Chief Executive Officer Albert Bourla told Bloomberg in late July that the company would expand the size of its trial in young children, but the drug giant hasn’t yet disclosed how many will ultimately be enrolled.

Source: Mint August 11, 2021 17:37 UTC